{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:20:41Z","timestamp":1771464041365,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No 81521005"],"award-info":[{"award-number":["No 81521005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["No XDA12050306"],"award-info":[{"award-number":["No XDA12050306"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10637-021-01071-z","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T18:02:52Z","timestamp":1611770572000},"page":"1011-1018","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers"],"prefix":"10.1007","volume":"39","author":[{"given":"Yun-ting","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-fang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-xia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-jing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-fang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"1071_CR1","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1007\/s00432-020-03311-w","volume":"146","author":"T Landre","year":"2020","unstructured":"Landre T, Des Guetz G, Chouahnia K, Duchemann B, Assi\u00e9 JB, Chouaid C (2020) First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. J Cancer Res Clin Oncol 146:3333\u20133339. https:\/\/doi.org\/10.1007\/s00432-020-03311-w","journal-title":"J Cancer Res Clin Oncol"},{"key":"1071_CR2","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.21037\/jtd.2019.08.32","volume":"12","author":"JA Chen","year":"2020","unstructured":"Chen JA, Riess JW (2020) Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. J Thoracic Dis 12:2859\u20132876. https:\/\/doi.org\/10.21037\/jtd.2019.08.32","journal-title":"J Thoracic Dis"},{"key":"1071_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11864-018-0570-9","volume":"19","author":"HH Loong","year":"2018","unstructured":"Loong HH, Kwan SS, Mok TS, Lau YM (2018) Therapeutic strategies in EGFR mutant non-small cell lung cancer. Curr Treat Options in Oncol 19:58. https:\/\/doi.org\/10.1007\/s11864-018-0570-9","journal-title":"Curr Treat Options in Oncol"},{"key":"1071_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-3-319-91442-8_14","volume":"211","author":"H Wecker","year":"2018","unstructured":"Wecker H, Waller CF (2018) Afatinib. Recent Results Cancer Res 211:199\u2013215. https:\/\/doi.org\/10.1007\/978-3-319-91442-8_14","journal-title":"Recent Results Cancer Res"},{"key":"1071_CR5","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/cancers12061587","volume":"12","author":"J Li","year":"2020","unstructured":"Li J, Kwok HF (2020) Current strategies for treating NSCLC: from biological mechanisms to clinical treatment. Cancers (Basel) 12:1587. https:\/\/doi.org\/10.3390\/cancers12061587","journal-title":"Cancers (Basel)"},{"key":"1071_CR6","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.21037\/tlcr.2019.06.01","volume":"8","author":"NM Andrews Wright","year":"2019","unstructured":"Andrews Wright NM, Goss GD (2019) Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl Lung Cancer Res 8:S247\u2013S264. https:\/\/doi.org\/10.21037\/tlcr.2019.06.01","journal-title":"Transl Lung Cancer Res"},{"key":"1071_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"ZF Lim","year":"2019","unstructured":"Lim ZF, Ma PC (2019) Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol 12:134. https:\/\/doi.org\/10.1186\/s13045-019-0818-2","journal-title":"J Hematol Oncol"},{"key":"1071_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/lctt.s119644","volume":"8","author":"M Santarpia","year":"2017","unstructured":"Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffin\u00e0 MG, D'Aveni A, Marabello G, Altavilla G, Rosell R (2017) Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl) 8:109\u2013125. https:\/\/doi.org\/10.2147\/lctt.s119644","journal-title":"Lung Cancer (Auckl)"},{"key":"1071_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11523-017-0519-0","volume":"12","author":"YN Lamb","year":"2017","unstructured":"Lamb YN, Scott LJ (2017) Osimertinib: a review in T790M-positive advanced non-small cell lung Cancer. Target Oncol 12:555\u2013562. https:\/\/doi.org\/10.1007\/s11523-017-0519-0","journal-title":"Target Oncol"},{"key":"1071_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","volume":"15","author":"Y Shi","year":"2020","unstructured":"Shi Y, Zhang S, Hu X, Feng J, Ma Z, Zhou J, Yang N, Wu L, Liao W, Zhong D, Han X, Wang Z, Zhang X, Qin S, Ying K, Feng J, Fang J, Liu L, Jiang Y (2020) Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. J Thorac Oncol 15:1015\u20131026. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.010","journal-title":"J Thorac Oncol"},{"key":"1071_CR11","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s41401-020-0389-3","volume":"41","author":"XY Liu","year":"2020","unstructured":"Liu XY, Guo ZT, Chen ZD, Zhang YF, Zhou JL, Jiang Y, Zhao QY, Diao XX, Zhong DF (2020) Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacol Sin 41:1366\u20131376. https:\/\/doi.org\/10.1038\/s41401-020-0389-3","journal-title":"Acta Pharmacol Sin"},{"key":"1071_CR12","doi-asserted-by":"publisher","first-page":"112735","DOI":"10.1016\/j.jpba.2019.06.032","volume":"176","author":"X Liu","year":"2019","unstructured":"Liu X, Li W, Zhang Y, Jiang Y, Zhao Q, Zhong D (2019) Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 176:112735. https:\/\/doi.org\/10.1016\/j.jpba.2019.06.032","journal-title":"J Pharm Biomed Anal"},{"key":"1071_CR13","unstructured":"US Food and Drug Administration: Center for Drug Evaluation and Research (CDER) (2020) Guidance for industry: clinical drug interaction studies-cytochrome P450 enzyme- and transporter-mediated drug interactions. US Food and Drug Administration"},{"key":"1071_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40261-014-0217-y","volume":"34","author":"RC Shumaker","year":"2014","unstructured":"Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M (2014) Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Invest 34:651\u2013659. https:\/\/doi.org\/10.1007\/s40261-014-0217-y","journal-title":"Clin Drug Invest"},{"key":"1071_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s13318-018-0467-9","volume":"43","author":"D Luedtke","year":"2018","unstructured":"Luedtke D, Marzin K, Jungnik A, von Wangenheim U, Dallinger C (2018) Effects of ketoconazole and rifampicin on the pharmacokinetics of Nintedanib in healthy subjects. Eur J Drug Metab Pharmacokinet 43:533\u2013541. https:\/\/doi.org\/10.1007\/s13318-018-0467-9","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1071_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/11586980-000000000-00000","volume":"11","author":"P Martin","year":"2011","unstructured":"Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T (2011) Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R&D 11:37\u201351. https:\/\/doi.org\/10.2165\/11586980-000000000-00000","journal-title":"Drugs R&D"},{"key":"1071_CR17","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/bcp.13534","volume":"84","author":"K Vishwanathan","year":"2018","unstructured":"Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeno J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD (2018) The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol 84:1156\u20131169. https:\/\/doi.org\/10.1111\/bcp.13534","journal-title":"Br J Clin Pharmacol"},{"key":"1071_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","volume":"59","author":"M Elmeliegy","year":"2020","unstructured":"Elmeliegy M, Vourvahis M, Guo C, Wang DD (2020) Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet 59:699\u2013714. https:\/\/doi.org\/10.1007\/s40262-020-00867-1","journal-title":"Clin Pharmacokinet"},{"key":"1071_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2133\/dmpk.21.297","volume":"21","author":"M Nishimura","year":"2006","unstructured":"Nishimura M, Koeda A, Suzuki E, Kawano Y, Nakayama M, Satoh T, Narimatsu S, Naito S (2006) Regulation of mRNA expression of MDR1, MRP1, MRP2 and MRP3 by prototypical microsomal enzyme inducers in primary cultures of human and rat hepatocytes. Drug Metab Dispos 21:297\u2013307. https:\/\/doi.org\/10.2133\/dmpk.21.297","journal-title":"Drug Metab Dispos"},{"key":"1071_CR20","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1124\/dmd.115.069203","volume":"44","author":"PA Dickinson","year":"2016","unstructured":"Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P (2016) Metabolic disposition of Osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos 44:1201\u20131212. https:\/\/doi.org\/10.1124\/dmd.115.069203","journal-title":"Drug Metab Dispos"},{"key":"1071_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1124\/dmd.111.038067","volume":"39","author":"Y Xu","year":"2011","unstructured":"Xu Y, Zhou Y, Hayashi M, Shou M, Skiles GL (2011) Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab Dispos 39:1139\u20131148. https:\/\/doi.org\/10.1124\/dmd.111.038067","journal-title":"Drug Metab Dispos"},{"key":"1071_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1124\/dmd.115.067173","volume":"44","author":"V Dixit","year":"2016","unstructured":"Dixit V, Moore A, Tsao H, Hariparsad N (2016) Application of micropatterned cocultured hepatocytes to evaluate the inductive potential and degradation rate of major xenobiotic metabolizing enzymes. Drug Metab Dispos 44:250\u2013261. https:\/\/doi.org\/10.1124\/dmd.115.067173","journal-title":"Drug Metab Dispos"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01071-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01071-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01071-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:05:34Z","timestamp":1678511134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01071-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01071-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,27]]},"assertion":[{"value":"23 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jing-jing Bao was the employee of Shanghai Allist Pharmaceuticals Co., Ltd. at the time the study was conducted. The remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The study protocol was approved by the Independent Ethics Committee of the hospital, and was carried out in full compliance with the principles of the \u2018Declaration of Helsinki\u2019 (current revision) and \u2018Good Clinical Practice\u2019 guideline. Written informed consent was obtained from all participants before the start of treatment or any study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript and agree with its publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication (include appropriate statements)"}},{"value":"This is a research involving human participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}